National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Rivaroxaban (Xarelto®) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

NCPE Assessment Process Complete
Rapid review commissioned 26/09/2018
Rapid review completed 11/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.